Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined molecular subclass and immune phenotype correlate to atezolizumab plus radiation therapy response in invasive bladder cancer: BPT-ART Phase II study.
Nagumo Y, Hattori K, Kimura T, Sekino Y, Naiki T, Kobayashi Y, Matsumoto T, Osawa T, Kita Y, Takemura M, Mathis BJ, Suzuki S, Tsuzuki T, Ishikawa H, Nishiyama H. Nagumo Y, et al. Among authors: kita y. Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03774-X. doi: 10.1016/j.ijrobp.2024.12.019. Online ahead of print. Int J Radiat Oncol Biol Phys. 2025. PMID: 39755215
Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.
Yoshida T, Ohe C, Ito K, Takada H, Saito R, Kita Y, Sano T, Tsuta K, Kinoshita H, Kitamura H, Nishiyama H, Kobayashi T; Japan Urological Oncology Group. Yoshida T, et al. Among authors: kita y. Cancer Immunol Immunother. 2022 Nov;71(11):2815-2828. doi: 10.1007/s00262-022-03204-6. Epub 2022 Apr 20. Cancer Immunol Immunother. 2022. PMID: 35445305 Free PMC article.
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.
Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T. Kita Y, et al. Urol Oncol. 2022 Sep;40(9):410.e11-410.e18. doi: 10.1016/j.urolonc.2022.04.005. Epub 2022 May 9. Urol Oncol. 2022. PMID: 35551861
Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kita Y, Otsuka H, Ito K, Hara T, Shimura S, Kawahara T, Kato M, Kanamaru S, Inoue K, Ito H, Igarashi A, Sazuka T, Takamatsu D, Hashimoto K, Abe T, Naito S, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kita Y, et al. Int J Urol. 2024 May;31(5):552-559. doi: 10.1111/iju.15411. Epub 2024 Feb 1. Int J Urol. 2024. PMID: 38303567 Free PMC article.
Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y, Ito K, Sano T, Hashimoto K, Mochizuki T, Shiraishi Y, Araki H, Fujiwara M, Kanamaru S, Takahashi T, Hishiki K, Okada T, Ogawa K, Ito M, Kojima T, Nishiyama N, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T. Kita Y, et al. Int J Urol. 2022 Jul;29(7):647-655. doi: 10.1111/iju.14861. Epub 2022 Mar 18. Int J Urol. 2022. PMID: 35304776
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Ito K, Kita Y, Yokomizo A, Miki J, Yoshio Y, Matsumoto H, Segawa T, Karashima T, Nishiyama N, Imai K, Suekane S, Nagasawa S, Higashi S, Nishiyama H, Kitamura H, Kobayashi T. Ito K, et al. Among authors: kita y. Cancer Med. 2023 Feb;12(3):2325-2332. doi: 10.1002/cam4.5057. Epub 2022 Jul 21. Cancer Med. 2023. PMID: 35864744 Free PMC article.
Spatial Pattern of Intraprostatic Recurrence after Definitive External-Beam Radiation Therapy for Prostate Cancer: Implications for Focal Boost to Intraprostatic Dominant Lesion.
Aizawa R, Otani T, Ogata T, Moribata Y, Kido A, Akamatsu S, Goto T, Masui K, Sumiyoshi T, Kita Y, Kobayashi T, Nakamoto Y, Mizowaki T. Aizawa R, et al. Among authors: kita y. Adv Radiat Oncol. 2024 Mar 13;9(6):101489. doi: 10.1016/j.adro.2024.101489. eCollection 2024 Jun. Adv Radiat Oncol. 2024. PMID: 38681892 Free PMC article.
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: kita y. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab.
Sakatani T, Kita Y, Fujimoto M, Sano T, Hamada A, Nakamura K, Takada H, Goto T, Sawada A, Akamatsu S, Kobayashi T. Sakatani T, et al. Among authors: kita y. Cancers (Basel). 2022 Jan 6;14(2):263. doi: 10.3390/cancers14020263. Cancers (Basel). 2022. PMID: 35053427 Free PMC article.
1,573 results